Navigation Links
BioParadox Announces Partnership with Fogarty Institute for Innovation
Date:2/2/2012

MENLO PARK, Calif., Feb. 2, 2012 /PRNewswire/ -- BioParadox, Inc., a regenerative medicine company pioneering point-of-care biologic treatments for cardiovascular disease, today announced a strategic alliance with Fogarty Institute for Innovation. 

"We are delighted to begin working with the Fogarty Institute for Innovation known for its commitment to developing creative solutions for patients with challenging problems.  The Fogarty Institute's unique programs to support medical innovators by providing important business, technical, and clinical input offers BioParadox the opportunity to rapidly advance its novel Platelet-Cell Therapy (PCT) for the treatment of cardiovascular disease," said Allan Mishra, MD, Founder of BioParadox. 

Speaking at the January 2012 Conference on Cell Therapy for Cardiovascular Disease in New York, Todd Brinton, MD, presented data supporting PCT for peripheral vascular disease.  BioParadox was also recently awarded a United States patent covering this technology. 

About BioParadox

BioParadox is innovating the use of Platelet-Cell Therapy (PCT) for the treatment of cardiovascular disease. The company's first products, VitaKine® and RevaTen®, are proprietary formulations that have been shown to enhance cardiovascular function. They are produced exclusively by BioParadox.

For more information, please visit: BioParadox.com or e-mail: info@bioparadox.com

About the Fogarty Institute for Innovation

The Fogarty Institute for Innovation is an educational 501(c) (3) non-profit committed to the mission of improving patient care by supporting revolutionary medical innovation. The Institute offers promising innovators world-class technical and business mentoring, laboratory space, and clinical support to propel medical innovations from conception to application. Further information is available at www.fogartyinstitute.org.


'/>"/>
SOURCE BioParadox, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regenerative Medicine Company BioParadox adds Healthcare and Medical Device Expert, Michael Kleine, to its Board of Directors
2. Hybrid Fuels, Inc. Announces FDA Approved Lab Selection for Azul Instant™ - "Be Ready in an Instant"
3. Nautilus Neurosciences Announces New Patent Issued
4. Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe
5. Sapio Sciences Announces Exemplar Dx LIMS for Laboratories in the Burgeoning MDx Market
6. Medical Alarm to Begin Fulfillment of MediPendant™ Against Largest Purchase Order - Announces Additional Warrant Cancellations
7. RemedyMD Announces Investigate Cell Therapy, a Revolutionary Research Management System for Blood and Marrow Transplant Centers
8. China Health Resource Announces Professor Liang Li, World Renowned TCM Expert, to Lead Gastrodia Deep Processing Research
9. Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing Authorisation and Requests Further Information From the CHMP
10. IDEXX Laboratories Announces Fourth Quarter and Full Year Results
11. Oclaro Announces Second Quarter Fiscal Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
(Date:9/1/2017)...  Bayer will present the latest research from across its ... (ESMO) 2017 Congress, September 8-12 in Madrid, Spain ... clinical data on Bayer,s marketed portfolio and late-stage compounds as ... "We value the opportunity to ... at ESMO," said Carsten Brunn , Head of Pharmaceuticals, ...
(Date:8/29/2017)... 29, 2017 In a move that promises ... compliance for veterinary practices of all sizes, Cubex LLC ... that makes TITAN,s expertise in physical security, drug diversion ... clients nationally. ... controlled substances is at risk today," said TITAN founder ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... Trusted debt-reduction firm CreditAssociates, LLC has announced two ... in excess of $835 million in resolved debt for its clients. , Credit card ... of the categories of debt settled by the company. With more than a decade ...
(Date:9/19/2017)... ... September 19, 2017 , ... Arizona-based ... as the President of its HealthBI division. McFarland will grow the organization’s ... , “Scott is a utility player who balances his day as a ...
(Date:9/19/2017)... Hill, CT (PRWEB) , ... September 19, 2017 ... ... support, today announced the winners of the Entrepreneur Innovation Awards (EIA), held this ... all of whom are Connecticut-based companies and entrepreneurs, presented their innovative project ideas ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, has introduced a new ... we’re born, Nature gives us a full supply of melanin – in the back ... this natural glare-reducing pigment; however, around the age of thirty, we develop a yellow-brown ...
(Date:9/19/2017)... ... September 19, 2017 , ... Presenting its annual ... (SPBA) hosted “Expanding Your Success” with an educational emphasis. , The three-day ... best practices for third party administrators (TPAs) related to health plan management and ...
Breaking Medicine News(10 mins):